Covid-19 roundup: FDA stamps quick OK on Roche's Actem­ra PhI­II; AlloVir ex­pands Bay­lor pact

→ The FDA has of­fered a quick OK for Genen­tech to start a Phase III tri­al us­ing their rheuma­toid arthri­tis drug Actem­ra against Covid-19. And the big Roche sub­sidiary is send­ing in 10,000 dos­es for the US stock­pile.

Genen­tech is work­ing with BAR­DA on the study, which has es­tab­lished pri­ma­ry and sec­ondary end­points that in­clude “clin­i­cal sta­tus, mor­tal­i­ty, me­chan­i­cal ven­ti­la­tion and in­ten­sive care unit (ICU) vari­ables.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER